Varian Medical Systems (VAR) Appoints Rafael Torres Senior Vice President Of Business Development And Strategy

PALO ALTO, Calif., Sept. 30, 2015 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) has appointed Rafael Torres to the position of senior vice president, business development and strategy.  In this role, he leads the company's strategic plans for growth through acquisitions, investments, and partnerships that complement our current portfolio of businesses.  He reports to Varian President and CEO Dow Wilson.

Rafael Torres, Senior Vice President of Business Development and Strategy at Varian Medical Systems
"Rafael Torres is uniquely qualified to lead our strategy and business development activities," said Wilson.  "He brings over 14 years of healthcare strategic investing and business development experience, having served as global head of healthcare for GE Ventures and GE Equity, where he built a strategic investment portfolio of over 30 healthcare companies.  He has significant global business development experience, which will be a tremendous asset as Varian continues to emphasize globalization of its market and operations."

"It's an exciting time to join Varian, as the company is poised to take advantage of significant growth and expansion opportunities that leverage its market leadership in cancer treatment and imaging," said Torres. "With stakeholders navigating the current transition away from 'fee for service' to a 'fee for value' model in healthcare, our technologies and business models must support them in this transformation.  Our growth themes will support Varian's globalization and foster a culture of disruptive innovation in order to maintain a technology leadership position."

Prior to joining Varian, Torres served as global head of healthcare for GE Ventures and GE Equity.  He was a founding member of GE Ventures and a member of its senior leadership committee.  Torres led the healthcare investment team and represented GE on portfolio company boards, including CardioDx, InSightec, LipoScience, Navinet and ParadigmHealth.

Torres was also a judge of the healthymagination Cancer Innovation Challenge and a member of the StartupHealth transformers advisory panel.  He has been featured in healthcare publications and conferences including The Gray Sheet, MedDevice Daily, SXSW, Slush Digital Health and Biomed Israel.  He held previous roles at The Boston Consulting Group and Citibank N.A.

Torres holds an MBA degree from Harvard Business School and a B.A. in economics from the Universidad del Pacifico in Lima, Peru.  

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and for X-ray imaging.  The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiation. The company provides comprehensive solutions for radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors, and image processing software and workstations for use in medical, scientific, and industrial settings, as well as for security and non-destructive testing.  Varian Medical Systems employs approximately 6,900 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world.  For more information, visit http://www.varian.com or follow us on Twitter.

Forward-Looking Statements
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry and market outlook, the company's future performance, growth, strategies and opportunities, and any statements using the terms "will," "poised," "growth," "maintain," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the ability to retain the services of key personnel; the company's ability to capitalize on strategic opportunities and to develop, commercialize, and deploy new products; the impact of competitive products and strategies; the effect of global economic conditions; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

FOR INFORMATION CONTACT:
Varian Medical Systems
Meryl Ginsberg, 650.424.6444
[email protected]

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.